Fulminant Liver Failure Clinical Trial
Official title:
The Use of Human Hepatocyte Transplantation as a Life Support Bridge in Terminal Liver Failure
The purpose of this study is to gain knowledge about the result of infusing liver cells, carefully matched to blood type, into a subject's body. The hope is that this procedure will aid functions of the liver and prevent death, enable a transplant procedure to be carried out if a donated liver becomes available, and lessen complications in postoperative recovery. There is no guarantee that any of these benefits will be re eived, but even if they are not, the hope is that knowledge gained by using this procedure will be of future benefit to others who also suffer from liver disease.
Adult and pediatric patients eligible for liver transplantation who require intensive care
unit admission for multisystem organ failure in addition to liver failure, without systemic
sepsis, are eligible for liver cell transplantation regardless of race, sex or financial
support.
Failure of 3 or more organ systems are the criterion used to select patients with as close
to 100% mortality as possible without solid organ transplant.
Hepatocytes, isolated from excess liver tissure from reduced liver transplant procedures or
from donor livers not used for transplantation, are prepared by a complex process and then
are infused, guided by radiology into the splenic artery or portal vein of the patient.
Patients must be on immunosuppression therapy for as long as the hepatocytes are living and
beneficial to the patient.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02503384 -
Clinical and Basic Study for Pediatric Liver Transplantation
|
N/A |